With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near

Submitted by admin on September 30, 2024 - 9:57am

Source:

Fierce Biotech

News Tags:

BridgeBio

acoramidis

FDA

transthyretin amyloid cardiomyopathy

Headline:

With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near

snippet:

BridgeBio Pharma has been on the road to redemption ever since its treatment for a rare and fatal heart condition, acoramidis, flopped in an early readout of phase 3 data.

Search form

You are here

With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near

With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near